Bioavailability of two sublingual formulations of ketorolac tromethamine 30 mg: A randomized, open-label, single-dose, two-period crossover comparison in healthy mexican adult volunteers

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1667-1674

  Galán Herrera, Juan Francisco ^a   Poo, Jorge Luis ^a   Maya Barrios, Jose Alfonso ^a   de Lago, Alberto ^b   Oliva, Iván ^b   González de la Parra, Mario ^b   Jiménez, Patricia ^b   López Bojórquez, Ericka ^b   Burke Fraga, Victoria ^b   Namur, Salvador ^b  

^a LIVER RESEARCH UNIT   (Mexico)

^b Fundacion Liomont AC   (Mexico)

Author keywords

bioavailability; bioequivalence; HPLC; ketorolac; ketorolac tromethamine; pharmacokinetic

Indexed keywords

IBUPROFEN; KETOROLAC TROMETAMOL; PARACETAMOL; SUPRADOL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM PERFORATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MEXICO; NAUSEA; NORMAL HUMAN; OPEN STUDY; OTALGIA; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HUMANS; KETOROLAC TROMETHAMINE; MALE; MEXICO; MIDDLE AGED; NONTHERAPEUTIC HUMAN EXPERIMENTATION; REFERENCE VALUES; THERAPEUTIC EQUIVALENCY;

EID: 53049097301     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.011     Document Type: Article

References (26)

1. Buckley M.M., and Brogden R.N. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 39 (1990) 86-109
2. Rooks II W.H., Tomolonis A.J., Maloney P.J., et al. The analgesic and anti-inflammatory profile of (+/-)-5-benzoyl-1,2- dihydro-3H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (RS-37619). Agents Actions 12 (1982) 684-690
3. Rauk P.N., and Laifer S.A. The prostaglandin synthesis inhibitor ketorolac blocks ritodrine-stimulated production of prostaglandin F2 alpha in pregnant sheep. Obstet Gynecol 81 (1993) 323-326
4. Malmberg A.B., and Yaksh T.L. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257 (1992) 1276-1279
5. Maves T.J., Pechman P.S., Meller S.T., and Gebhart G.F. Ketorolac potentiates morphine antinociception during visceral nociception in the rat. Anesthesiology 80 (1994) 1094-1101
6. Tripathi A., and Welch S.P. Blockade of the antinociceptive activity of centrally administered ketorolac by norbinaltorphimine. Eur J Pharmacol 278 (1995) 27-32
7. Granados-Soto V., Flores-Murrieta F.J., Castañeda-Hernández G., et al. Evidence against the participation of mu- and kappa-opioid receptors in the analgesic activity of ketorolac in rats. J Pharm Pharmacol 47 (1995) 514-517
8. Negus S.S., Butelman E.R., Gatch M.B., and Woods J.H. Effects of morphine and ketorolac on thermal allodynia induced by prostaglandin E2 and bradykinin in rhesus monkeys. J Pharmacol Exp Ther 274 (1995) 805-814
9. Domer F. Characterization of the analgesic activity of ketorolac in mice. Eur J Pharmacol 177 (1990) 127-135
10. Flores-Murrieta F.J., and Granados-Soto V. Pharmacologic properties of ketorolac tromethamine: A potent analgesic drug. CNS Drug Reviews 2 (1996) 75-90
11. Wiedrick J.E., Friesen E.G., Garton A.M., and Otten N.H. Upper gastrointestinal bleeding associated with oral ketorolac therapy. Ann Pharmacother 28 (1994) 1109
12. Granados-Soto V., Flores-Murrieta F.J., Castañeda-Hernández G., and López-Muñoz F.J. Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac. Eur J Pharmacol 277 (1995) 281-284
13. Welch S.P. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyltyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 265 (1993) 633-640
14. Chàvez R., Bravo C., Zazueta C., et al. Ionophoretic-like properties of ketorolac for calcium. J Pharmacol Exp Ther 267 (1993) 1134-1139
15. Pérez-Urizar J., Aguilar-Cota M.E., Herrera J.E., and Flores-Murrieta F.J. Comparative bioavailability of ketorolac tromethamine after intramuscular and sublingual administration. Proc West Pharmacol Soc 45 (2002) 6-7
16. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 7, 2000.
17. http://www.wma.net/e/policy/b3.htm Accessed December 6, 2007
18. European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice [EMEA Web site]. ICH topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed December 10, 2007
19. Ministry of Health of Mexico. Federal Commission of Protection Against Sanitary Risks [in Spanish] [Secretaría de Salud Web site]
20. http://portal.salud.gob.mx Accessed September 26, 2007
21. Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations. US Department of Health and Human Services. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER), March 2003 [FDA Web site]
22. http://www.fda.gov/cder/guidance/5356fnl.pdf Accessed September 8, 2008
23. Piñeyro-López A., Piñeyro-Garza E., Torres-Alanís O., et al. Bioavailability of two oral formulations of azithromycin 500 mg: A randomized, open-label, two-period crossover comparison in healthy Mexican adult subjects. Clin Ther 27 (2005) 1607-1611
24. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15 (1987) 657-680
25. Chow S.-C., and Liu J.-P. Statistical methods for average bioavailability. Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY 79-124
26. In: Chow S.-C., and Liu J.-P. (Eds). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd ed (2000), Marcel Dekker, New York, NY 125-160